Comparative Pharmacology
Head-to-head clinical analysis: DELTASONE versus FLORONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELTASONE versus FLORONE.
DELTASONE vs FLORONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prednisone is a prodrug that is converted to prednisolone, which binds to the glucocorticoid receptor, leading to altered gene expression and suppression of inflammatory mediators, immune cells, and cytokine production.
Glucocorticoid receptor agonist; induces phospholipase A2 inhibitory proteins (lipocortins), which suppress release of arachidonic acid and subsequent prostaglandin/leukotriene synthesis; also suppresses cytokine production and immune cell migration.
5-60 mg orally once daily or divided twice daily; dose individualized based on condition and response.
Topical: Apply a thin layer to affected skin once or twice daily. Maximum use: 45 g/week.
None Documented
None Documented
The terminal elimination half-life of prednisolone (active form) is 2.1–3.5 hours. In clinical context, this short half-life supports once-daily to twice-daily dosing for anti-inflammatory effects, but adrenal suppression can persist longer due to receptor binding.
Terminal elimination half-life of approximately 2-3 hours; clinical context: duration of action may extend beyond half-life due to tissue binding.
Prednisone is a prodrug converted to prednisolone. Prednisolone is metabolized primarily in the liver. Renal excretion of unchanged drug is negligible (<1%). Metabolites are excreted renally (approximately 80% as glucuronides and sulfates) and to a small extent in feces (<5%). Biliary excretion is minimal.
Renal (approximately 80% as metabolites, <5% unchanged), biliary/fecal (remainder).
Category C
Category C
Corticosteroid
Corticosteroid